Song, Jie http://orcid.org/0000-0002-7357-2136
Yao, Shuyang http://orcid.org/0000-0001-9669-4470
Kowalec, Kaarina http://orcid.org/0000-0003-3928-9879
Lu, Yi http://orcid.org/0000-0001-9933-3654
Sariaslan, Amir
Szatkiewicz, Jin P. http://orcid.org/0000-0002-4898-7401
Larsson, Henrik
Lichtenstein, Paul http://orcid.org/0000-0003-3037-5287
Hultman, Christina M.
Sullivan, Patrick F. http://orcid.org/0000-0002-6619-873X
Funding for this research was provided by:
Vetenskapsrådet (D0886501)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (U01 MH109528)
Article History
Received: 29 April 2021
Revised: 14 February 2022
Accepted: 22 February 2022
First Online: 5 April 2022
Competing interests
: PFS reports potentially competing financial interests: Lundbeck (grant recipient), Neumora Therapeutics (advisory committee, shareholder). HL has served as a speaker for Evolan Pharma and Shire and has received research grants from Shire; all outside the submitted work. The other authors report no financial COI.